MX2016008815A - Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de celulas renales (rcc). - Google Patents

Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de celulas renales (rcc).

Info

Publication number
MX2016008815A
MX2016008815A MX2016008815A MX2016008815A MX2016008815A MX 2016008815 A MX2016008815 A MX 2016008815A MX 2016008815 A MX2016008815 A MX 2016008815A MX 2016008815 A MX2016008815 A MX 2016008815A MX 2016008815 A MX2016008815 A MX 2016008815A
Authority
MX
Mexico
Prior art keywords
rcc
dihydro
oxo
treatment
cell carcinoma
Prior art date
Application number
MX2016008815A
Other languages
English (en)
Inventor
Bladt Friedhelm
Friese-Hamim Manja
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2016008815A publication Critical patent/MX2016008815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

3- (1-{3- [5- (1-metil-piperidin-4-ilmetoxi) -pirimidin-2-il] -bencil} -6-oxo-1,6-dihidro-piridazin-3-il) -benzonitrilo o una sal farmacéuticamente aceptable y/o solvato del mismo para usarse en el tratamiento de carcinoma de células renales (RCC).
MX2016008815A 2014-01-07 2014-12-16 Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de celulas renales (rcc). MX2016008815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14000036 2014-01-07
PCT/EP2014/003365 WO2015104042A1 (en) 2014-01-07 2014-12-16 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)

Publications (1)

Publication Number Publication Date
MX2016008815A true MX2016008815A (es) 2016-09-08

Family

ID=49916969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008815A MX2016008815A (es) 2014-01-07 2014-12-16 Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de celulas renales (rcc).

Country Status (17)

Country Link
US (1) US20160331748A1 (es)
EP (1) EP3091980A1 (es)
JP (1) JP2017502978A (es)
KR (1) KR20160099724A (es)
CN (1) CN105873591A (es)
AR (1) AR099035A1 (es)
AU (1) AU2014377079A1 (es)
CA (1) CA2935889C (es)
CL (1) CL2016001726A1 (es)
IL (1) IL246628A0 (es)
MX (1) MX2016008815A (es)
MY (1) MY191613A (es)
PH (1) PH12016500964A1 (es)
RU (1) RU2016132401A (es)
SG (1) SG11201605501RA (es)
TW (1) TW201609103A (es)
WO (1) WO2015104042A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146384A1 (en) * 2019-07-10 2021-01-14 Merck Patent Gmbh Pharmaceutical preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
SG10201504735QA (en) * 2009-01-08 2015-07-30 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
CA2935889C (en) 2022-08-16
NZ722879A (en) 2021-08-27
SG11201605501RA (en) 2016-08-30
TW201609103A (zh) 2016-03-16
JP2017502978A (ja) 2017-01-26
CL2016001726A1 (es) 2016-12-16
CA2935889A1 (en) 2015-07-16
US20160331748A1 (en) 2016-11-17
IL246628A0 (en) 2016-08-31
PH12016500964A1 (en) 2016-06-20
RU2016132401A3 (es) 2018-08-29
MY191613A (en) 2022-07-03
WO2015104042A1 (en) 2015-07-16
EP3091980A1 (en) 2016-11-16
AU2014377079A1 (en) 2016-08-18
RU2016132401A (ru) 2018-02-13
AR099035A1 (es) 2016-06-22
KR20160099724A (ko) 2016-08-22
CN105873591A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
MX2016012058A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion.
MX2017009892A (es) Agente terapeutico contra el colangiocarcinoma.
CU24462B1 (es) Derivados de feniltriazol sustituido con hidroxialquilo
MX2019011789A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
IL251777B (en) 5-(3-hydroxy-propyn-1-yl)-3-pyrazol-4-yl)-indole derivatives as nick inhibitors
HK1263336A1 (zh) 含有1-(3-(2-(1-苯並噻吩-5-基-)乙氧基)丙基)氮雜環丁-3-醇或其鹽的片劑
IL252844B (en) Process for preparing 4-(3-(-6-cyano-5-(trifluoromethyl)pyridin-3-yl)-4-oxo-2-thio-3,1-diazaspiro[5,4]-octan-1-yl) -2- fluoro-n-methylbenzamide
EP3541796A4 (en) 4 - ((6- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
PH12017500719A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
MX2020002622A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
CL2017001478A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)
EP3541801A4 (en) 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
MX354518B (es) Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc).
PH12016500964A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
IL249248A0 (en) Non-aqueous crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-2,1-benzaisoxazole
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
PH12019501165A1 (en) Drug for treating cocaine addiction or preventing recurrence of same
ZA201801544B (en) 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts
DK3585776T3 (da) 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitril-forbindelser som ikke, tbk1 og/eller sik2 kinaseinhibitorer
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
UA98923U (ru) 3-((2-хлорэтил)тио)-4-этил-5(феноксиметил)-4н-1,2,4-триазола, проявляющей диуретическую активность
IL249496A0 (en) Improved process for the preparation of 4-(1-(4-(perfluoroethoxy)phenyl)-h4,2,1-1-triazol-3-yl)benzoyl azide
UA88008U (en) 3-(phenoxymethyl)-5-(propylthio)-1h-1,2,4-triazole exhibiting actoprotector activity